세계의 고혈압 치료제 시장 규모는 2024년-2030년의 예측기간 동안 복합 연간 성장률(CAGR) 3.3%의 성장이 예상됩니다. 고혈압 치료제 수요는 주로 고혈압의 유병률 증가, 비만과 과체중 사람들 증가, 고혈압과 관련된 영향에 대한 의식 증가, 특히 통제되지 않은 고혈압과 관련된 정신 질환 2024년에서 2030년 사이의 예측 기간 동안 시장의 전반적인 성장에 더욱 기여하고 있는 환자 증가에 의해 뒷받침되고 있습니다.
고혈압 치료제 시장 역학
세계보건기구(WHO)(2022)에 따르면 고혈압을 앓고 있는 30-79세의 인원수는 1990년 6억 5, 000만명에서 2019년 12억 8, 000만명으로 증가했습니다. 이 자료에 따르면 2019년10 억 명 이상의 고혈압 환자가 저중소득 국가에 거주했으며 여성의 고혈압 유병률이 가장 높았던 것은 도미니카 공화국, 자메이카, 파라과이에서 남성의 고혈압 유 병률이 가장 높았던 것은 헝가리, 파라과이, 폴란드였습니다.
고혈압은 심혈관 질환, 특히 관상 동맥 성 심장 질환과 뇌졸중, 만성 신장 질환, 심부전, 부정맥, 치매 등의 주요 위험 요소입니다. 따라서 고혈압의 유병률이 증가함에 따라 다른 치명적인 질병의 위험도 증가하여 건강 상태의 악화를 피하기 위해 고혈압 치료제에 대한 요구가 높아집니다.
우울증과 불안 장애와 같은 통제할 수 없는 고혈압의 원인이 되는 정신 질환의 병존 사례 증가는 고혈압 치료제 시장을 견인할 가능성이 높습니다. WHO(2022)에 따르면 2019년 전 세계에서 약 2억 8, 000만 명이 우울증을 앓고 있습니다.
세계의 과체중과 비만인 사람들 증가는 고혈압 치료제 시장의 성장을 자극하는 또 다른 요인입니다. World Obesity Federation(2022)에 따르면 2030년까지 세계의 약 10억 명(여성 5명 중 1명, 남성 7명 중 1명)이 비만과 함께 생활할 것으로 예상됩니다. 비만과 과체중 사람들은 항상 고혈압 및 기타 생활 습관병의 위험이 높습니다.
그러나 고혈압 치료제와 관련된 부작용과 고혈압 치료제의 리콜 증가는 고혈압 치료제 시장의 성장을 억제할 수 있습니다.
COVID-19 팬데믹은 고혈압 치료제 시장의 성장에 큰 영향을 미쳤습니다. 이는 COVID-19의 확대를 방지하기 위한 조치로서 락다운 지시가 내려져 고혈압 치료제 시장에서 제조, 가공, 공급, 유통, 수입, 수출, 기타 관련 활동의 정지로 이어진 것에 의한 물건이었습니다. 고혈압 환자의 우선순위가 낮아 의사의 진찰 횟수가 줄어들고 고혈압 치료제의 처방 횟수도 줄어듭니다. 그럼에도 불구하고 고혈압 치료제 시장은 의료 및 제약을 포함한 모든 부문에서의 활동 재개와 유행 후 과체중 및 비만 사람들 증가로 회복 국면에 있으며 예측기간 동안 고혈압 치료제가 큰 수익으로 성장하기에 충분한 기회가 있습니다.
고혈압 치료제 시장의 부문 분석
고혈압 치료제 시장의 약리학 부문에서 안지오텐신 전환효소(ACE) 억제제 카테고리는 2023년에 큰 수익 점유율을 획득할 것으로 예상됩니다. 이것은 고혈압 관리에서 ACE 억제제의 역할에 기인합니다.
ACE 억제제는 알도스테론이나 노르에피네프린 등 호르몬의 방출에 관여하고 고혈압으로 이어지는 혈관의 협착을 일으키는 물질인 안지오텐신 II의 생산에 관여하는 안지오텐신 변환효소의 작용을 저해함으로써 작용합니다.
이 약들은 정맥과 동맥을 이완시켜 혈압을 낮춥니다. ACE 억제제는 혈관을 넓히거나 확장하여 혈류량을 향상시키고 혈압을 낮춥니다. ACE 억제제는 심장의 혈액을 보내는 부담을 줄이고 고혈압으로 인한 모든 유형의 손상으로부터 신장을 보호합니다.
예를 들어, 캡토프릴(CAPOTEN)은 ACE 억제제의 일종으로 고혈압 치료에 적응합니다. 혈관을 이완시켜 혈액이 흐르기 쉽도록 작용합니다.
본 보고서에서는 세계의 고혈압 치료제 시장에 대한 조사 분석을 실시하고, 시장 규모와 예측, 촉진요인과 과제, 기업과 제품프로파일 등의 정보를 제공합니다.
The Hypertension Drugs Market By Pharmacological Class (Beta-Blockers, Diuretics, Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Antagonists, Renin Inhibitors, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising number of individuals with hypertension and growing awareness on high blood pressure
The global hypertension drugs market is estimated to grow at a CAGR of 3.3% during the forecast period from 2024 to 2030. The demand for hypertension drugs is primarily being boosted by the growing prevalence of hypertension, the rising number of obese and overweight individuals, growing awareness of high blood pressure and related consequences, and rising cases of psychiatric comorbidities associated with uncontrolled hypertension among others further contributing in the overall growth of the hypertension drugs market during the forecast period from 2024-2030.
Hypertension Drugs Market Dynamics:
As per the World Health Organization 2022, the number of individuals aged 30-79 years suffering from hypertension increased from 650 million in 1990 to 1.28 billion in 2019. As per the same source, in 2019, over 1 billion people with hypertension lived in low- and middle-income countries with Dominican Republic, Jamaica, and Paraguay recording the highest prevalence for hypertension in females while Hungary, Paraguay, and Poland had the highest rates of hypertension for males.
Hypertension is the major risk factor for cardiovascular diseases particularly coronary heart disease and stroke and also for diseases like chronic kidney disease, heart failure, arrhythmia, and dementia. So with the increasing prevalence of hypertension, the risk for other deadly diseases is going to increase and therefore will increase the need for hypertension drugs to avoid worse health outcomes.
The rising cases of psychiatric comorbidities such as depression, anxiety disorders, and others responsible for uncontrolled hypertension are likely to drive the market for hypertension drugs. According to WHO 2022, worldwide around 280 million people were suffering from depression in 2019.
The increasing number of overweight and obese individuals worldwide is another factor stimulating the growth of the hypertension drugs market. According to the World Obesity Federation 2022, it has been predicted that by 2030 about 1 billion people around the world, including 1 in 5 women and 1 in 7 men, will be living with obesity. Obese and overweight individuals are always at increased risk for hypertension and other lifestyle-related disorders.
However, side effects associated with hypertension drugs and an increasing number of hypertension drug recalls may restrict the growth of the hypertension drug market.
The COVID-19 pandemic had a significant impact on the growth of the hypertension drugs market. This was owing to lockdown impositions as a measure to prevent the spread of COVID-19 infection which led to a halt in manufacturing, processing, supply, distribution, import, export, and other related activities of the hypertension drugs market. The patients with hypertension were not on priority leading to a lack of doctor visits and fewer prescriptions for hypertension drugs. Nevertheless, the hypertension drugs market is in a recovery phase owing to the resumption of activities across all the sectors including healthcare and pharmaceutical, and due to the rise in the number of overweight and obese individuals post-pandemic, thereby providing ample opportunities for the hypertension drugs to grow at significant revenue during the forecast period.
Hypertension Drugs Market Segment Analysis:
Hypertension Drugs Market by Pharmacological Class (Beta-Blockers, Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Antagonists, Renin Inhibitors, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the pharmacological class segment of the hypertension drugs market, the angiotensin-converting enzyme (ACE) inhibitors category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the role of ACE inhibitors in the management of high blood pressure.
ACE inhibitors work by inhibiting the action of the angiotensin-converting enzyme which is involved in the production of angiotensin II, a substance responsible for the release of hormones such as aldosterone and norepinephrine and causing the narrowing of blood vessels leading to high blood pressure.
These medications help relax the veins and arteries to lower blood pressure. ACE inhibitors widen or dilate the blood vessels leading to improvement in the amount of blood flow and lowering of blood pressure. They allow the heart to work less strenuously to pump blood and help protect the kidney from any kind of damage due to hypertension.
For example, captopril (CAPOTEN) is an ACE inhibitor that is indicated for the treatment of hypertension. It works by causing the relaxation of blood vessels so that blood flows more easily.
Therefore, considering the advantages associated with angiotensin-converting enzyme inhibitors (ACE) and their growing popularity, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global hypertension drugs market during the forecast period.
North America is expected to dominate the overall Hypertension Drugs Market:
Among all the regions, North America is estimated to account for the largest share of the hypertension drugs market in the year 2023. Owing to the significance of key growth factors such as the increasing cases of hypertension, the escalating number of obese and overweight individuals in the region, sophisticated healthcare infrastructure, and fast regulatory approval for new products among others in the region the market for hypertension drugs is expected to grow during the forecast period.
As per the Centers for Disease Control and Prevention 2023, between 2017 and March 2020 about 48.1% of US adults aged 18 and above were suffering from hypertension. As per the same source around 56.8 million people visited physician's offices with essential hypertension as the primary diagnosis.
The above-mentioned source further stated that the number of visits to emergency departments with essential hypertension as the primary diagnosis was about 1.0 million in 2020 in the United States.
The increasing number of obese and overweight individuals in the region is going to accelerate the growth of the hypertension drugs market. As per data provided by the National Health and Nutrition Examination Survey (NHANES) (2023), the prevalence of obesity in 2020 was 41.9% in the US. Obesity is one of the major risk factors for hypertension.
Also, advanced product launches with numerous products receiving regulatory approval are further expected to fuel the market of hypertension drugs in the United States. For example, in August 2022, Alembic Pharma received the US Food and Drug Administration for chlorthalidone tablets indicated for the treatment of high blood pressure.
Hence, the above-mentioned factors are going to propel the growth of the hypertension drugs market in the region.
Hypertension Drugs Market Key Players:
Some of the key market players operating in the hypertension drugs market include Pharmanovia, Boehringer Ingelheim Ltd., DAIICHI SANKYO COMPANY, LIMITED, Lupin, Novartis AG, Merck & Co., Inc., Pfizer Inc., Sanofi, Noden Pharma DAC, Bayer, Zydus Cadila, Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hanmi Pharm. Co., Ltd., Mankind Pharma, GLENMARK PHARMACEUTICALS LTD., Ajanta Pharma, and others.
Recent Developmental Activities in the Hypertension Drugs Market:
In December 2022, Glenmark received the US FDA approval for the high blood pressure medicine Nicardipine Hydrochloride.
In September 2022, Lupin announced the launch of Sildenafil for oral suspension, indicated for the treatment of pulmonary arterial hypertension.
Key Takeaways from the Hypertension Drugs Market Report Study
Market size analysis for current hypertension drugs market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Hypertension drugs market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global hypertension drugs market.
Various opportunities available for the other competitor in the hypertension drugs market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current hypertension drugs market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for hypertension drugs market growth in the coming future?
Target Audience who can be benefited from this Hypertension Drugs Market Report Study
Hypertension drugs providers
Research organizations and consulting companies
Hypertension drugs- related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in hypertension drugs
Various End-users who want to know more about the hypertension drugs market and the latest innovations and developments in the hypertension drugs market.
Frequently Asked Questions for the Hypertension Drugs Market:
Hypertension drugs are medications meant for the treatment and management of patients suffering from hypertension. These medications lower blood pressure if lifestyle changes are not enough to bring one's blood pressure to the target level.
The global hypertension drugs market is estimated to grow at a CAGR of 3.3% during the forecast period from 2024 to 2030.
The growth of the hypertension drugs market is primarily being boosted by the increasing number of patients with hypertension, the surge in cases of psychiatric comorbidities worsening hypertension, and rising awareness campaigns on hypertension, among other factors that are contributing to the overall growth of the hypertension drugs market during the forecast period from 2024-2030.
Some of the key market players operating in the hypertension drugs market include Pharmanovia, Boehringer Ingelheim Ltd., DAIICHI SANKYO COMPANY, LIMITED, Lupin, Novartis AG, Merck & Co., Inc., Pfizer Inc., Sanofi, Noden Pharma DAC, Bayer, Zydus Cadila, Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hanmi Pharm. Co., Ltd., Mankind Pharma, GLENMARK PHARMACEUTICALS LTD., and others.
North America is expected to dominate the overall hypertension drugs market during the forecast period from 2024-2030. Factors such as the increasing number of obese and overweight individuals, the rising prevalence of hypertension, sophisticated healthcare infrastructure, regulatory approval for new products, and high awareness are driving the growth of the hypertension drugs market in the region.